Cargando…
Neither Tumor-Infiltrating Lymphocytes nor Cytotoxic T Cells Predict Enhanced Benefit from Chemotherapy in the DBCG77B Phase III Clinical Trial
SIMPLE SUMMARY: Apart from the direct killing of cancer cells, cyclophosphamide-based chemotherapy has been shown to induce an antitumor immune response, and is being used in combination with immunotherapies in cancer care. We assessed the interaction of chemotherapy with immune biomarkers expressed...
Autores principales: | Shenasa, Elahe, Stovgaard, Elisabeth Specht, Jensen, Maj-Britt, Asleh, Karama, Riaz, Nazia, Gao, Dongxia, Leung, Samuel, Ejlertsen, Bent, Laenkholm, Anne-Vibeke, Nielsen, Torsten O. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9367267/ https://www.ncbi.nlm.nih.gov/pubmed/35954471 http://dx.doi.org/10.3390/cancers14153808 |
Ejemplares similares
-
The immune microenvironment and relation to outcome in patients with advanced breast cancer treated with docetaxel with or without gemcitabine
por: Stovgaard, Elisabeth S, et al.
Publicado: (2021) -
Tumour-infiltrating lymphocytes and response to neoadjuvant letrozole in patients with early oestrogen receptor-positive breast cancer: analysis from a nationwide phase II DBCG trial
por: Skriver, Signe Korsgaard, et al.
Publicado: (2020) -
First-Line Treatment of HER2-Positive Metastatic Breast Cancer With
Dual Blockade Including Biosimilar Trastuzumab (SB3): Population-Based
Real-World Data From the DBCG
por: Celik, Alan, et al.
Publicado: (2022) -
Proteomics-derived basal biomarker DNA-PKcs is associated with intrinsic subtype and long-term clinical outcomes in breast cancer
por: Asleh, Karama, et al.
Publicado: (2021) -
Heterogeneity of triple negative breast cancer: Current advances in subtyping and treatment implications
por: Asleh, Karama, et al.
Publicado: (2022)